Lupin 2024

Dr. Daniel Holsworth of StemNext

Study by Tioga Research supports efficacy of liposomal compound Silvidiol

Study by Tioga Research supports efficacy of liposomal compound Silvidiol

HENDERSON, Nev. — Leading Edge Pharms, (LEP) a biotechnology company developing novel cannabinoid therapies and innovative delivery systems, announced the results of a Tioga Research-led study, indicating that its proprietary cannabidiol-based (CBD) pain relief and anti-inflammatory agent, Silvidiol, effectively permeates the epidermis to reach somatic and neuropathic sensory receptors below the surface of the skin.

PP_1170x120_10-25-21